Popular Trials
VEGF Antagonist
Aflibercept for Diabetic Macular Edema
Multicenter randomized trials have demonstrated the safety and efficacy of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of diabetic macular edema. The results are generally good in the short term, with approximately 75% of patients maintaining or improving vision after initiation of treatment. Despite this favorable outcome, the observation of persistent fluid is not infrequent during treatment, even in patients undergoing monthly treatment sessions. Persistent fluid was observed on optical coherence tomography (OCT) in 70.9% of patients receiving bevacizumab monthly and in 79% of those receiving bevacizumab as needed at the end of the first year in the Comparison of diabetic macular edema. Treatment Trials. It is possible that resolution of this fluid, especially when it is centrally located (i.e., foveal), might result in better visual outcomes. A drug with higher VEGF-binding affinity may help patients with persistent fluid despite treatment with bevacizumab. Aflibercept is a new intravitreal VEGF antagonist approved on 28 November 2014 by the Health Canada for the treatment of diabetic macular edema. In contrast to the antibody-based VEGF binding strategy used by bevacizumab, aflibercept incorporates the second binding domain of the VEGFR-1 receptor and the third domain of the VEGFR-2 receptor. By fusing these extracellular protein sequences to the Fc segment of a human IgG backbone, developers have created a chimeric protein with a very high VEGF binding affinity. Aflibercept binds all isomers of the VEGF-A family like bevacizumab, but it also binds VEGF-B and placental growth factors 1 and 2,1,2 which have been both implicated in the pathogenesis of diabetic retinopathy and of age-related macular degeneration. In addition, because of the increased trough binding activity and the stronger binding affinity, aflibercept should be efficacious in neutralizing VEGF more effectively and for longer duration.
Corticosteroid
Dexamethasone intravitreal implant +1 More for Retinal Vein Occlusion
This study seeks to compare dexamethasone implant with rescue intravitreal ranibizumab to monthly intravitreal ranibizumab for the treatment of macular edema secondary to branch or central retinal vein occlusion. This is based on the null hypothesis that dexamethasone implant with rescue ranibizumab has inferior best corrected visual acuity at six months compared to monthly ranibizumab alone.
Monoclonal Antibodies
Infliximab for Diabetic Macular Edema
This trial is testing if injecting infliximab into the eye can safely and effectively treat swelling in the eyes of people with diabetes. The goal is to see if this treatment can improve vision by reducing inflammation. Infliximab has been used in the past to treat various inflammatory eye conditions.
Popular Filters
Trials for Diabetic Macular Edema Patients
Monoclonal Antibodies
Foselutoclax for Diabetic Macular Edema
This trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
Corticosteroid
ILUVIEN® Implant for Diabetic Macular Edema
This trial is testing whether or not a new treatment for DME is better than the standard treatment. It will enroll patients who have not had any DME treatments for the past 12 months, and compare the new treatment to the standard treatment.
Monoclonal Antibodies
PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema
This trial will compare the effects of two different ways of delivering a drug to treat diabetic macular edema. One group will receive the drug every four weeks, and the other group will receive the drug every 24 weeks.
Trials for DME Patients
Monoclonal Antibodies
Foselutoclax for Diabetic Macular Edema
This trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
Corticosteroid
ILUVIEN® Implant for Diabetic Macular Edema
This trial is testing whether or not a new treatment for DME is better than the standard treatment. It will enroll patients who have not had any DME treatments for the past 12 months, and compare the new treatment to the standard treatment.
Monoclonal Antibodies
PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema
This trial will compare the effects of two different ways of delivering a drug to treat diabetic macular edema. One group will receive the drug every four weeks, and the other group will receive the drug every 24 weeks.
Phase 3 Trials
Monoclonal Antibodies
PDS with Ranibizumab vs. Intravitreal Ranibizumab for Diabetic Macular Edema
This trial will compare the effects of two different ways of delivering a drug to treat diabetic macular edema. One group will receive the drug every four weeks, and the other group will receive the drug every 24 weeks.
Vamikibart for Uveitic Macular Edema
This trial is testing vamikibart, a medication that may reduce eye swelling caused by inflammation. It focuses on people with uveitic macular edema, aiming to improve their condition by calming the inflammation in their eyes.
Trials With No Placebo
Monoclonal Antibodies
Foselutoclax for Diabetic Macular Edema
This trial is testing foselutoclax, a new drug, in patients with Diabetic Macular Edema who haven't responded to other treatments. The drug works by blocking a protein to reduce eye swelling and improve vision.
Corticosteroid
ILUVIEN® Implant for Diabetic Macular Edema
This trial is testing whether or not a new treatment for DME is better than the standard treatment. It will enroll patients who have not had any DME treatments for the past 12 months, and compare the new treatment to the standard treatment.
View More Related Trials
Frequently Asked Questions
Introduction to macular edema
What are the top hospitals conducting macular edema research?
In the realm of cutting-edge clinical trials addressing macular edema, several hospitals are at the forefront of medical research. In Boston, Ophthalmic Consultants of Boston leads the way with seven active trials dedicated to this condition and a remarkable 31 completed studies throughout their history. Their commitment to innovation started with their first recorded macular edema trial in 2004. Further west in Reno, Sierra Eye Associates is making significant contributions as well, having initiated their first trial in 2015 and currently conducting seven ongoing macular edema trials. Meanwhile, Cumberland Valley Retina Consultants in Hagerstown has also stepped up to the plate by undertaking seven active clinical trials for this condition since recording their inaugural study in 2017.
Additionally contributing towards advancing our understanding of macular edema is National Ophthalmic Research Institute located in Fort Myers where they presently have six ongoing investigations alongside previous twenty experiments conducted over years from initiating trail investigation on such conditions when it was founded back until2004.On top of all these efforts,Piedmont Eye Center situated within Lynchburg recently joined ranks pioneering themselves three years ago with earliest documented experimentation tracing back only two years ago-2018;nevertheless playing crucial role adding six current clinical tests upon prior total eleven examinations under its belt.
These esteemed institutions collectively embody true dedication to finding effective treatments for individuals impacted by macular edema. Each initiative brings us closer to unraveling the complexities surrounding this condition and offers hope for improved outcomes and quality of life for patients worldwide
Which are the best cities for macular edema clinical trials?
When it comes to macular edema clinical trials, several cities have emerged as leaders in research and innovation. Austin, Texas stands out with 21 active trials focusing on treatments like PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, Faricimab, KSI-301, and more. Hagerstown, Maryland follows closely behind with 18 ongoing studies exploring similar interventions such as PDS Implant Pre-Filled with 100 mg/mL Ranibizumab and RO7200220. San Antonio, Texas is also a prominent location for macular edema clinical trials, offering 16 active studies investigating treatments like PDS Implant Pre-Filled with 100 mg/mL Ranibizumab and KSI-301. These cities provide individuals affected by macular edema access to cutting-edge treatment options through their involvement in these important research endeavors.
Which are the top treatments for macular edema being explored in clinical trials?
Macular edema, a condition affecting the central vision of the eye, has spurred numerous clinical trials in search of effective treatments. Faricimab emerges as one of the top contenders, currently undergoing two active trials and having been listed since 2016 with a total of ten macular edema trials to date. Another promising treatment is the PDS Implant Pre-Filled with 100 mg/mL Ranibizumab, which also shows potential with two ongoing trials and an initial listing in 2019. Additionally, KSI-301 joins this lineup, participating in two active trials and four all-time macular edema studies since its introduction in 2018. These exploratory efforts bring us closer to finding innovative solutions for individuals suffering from macular edema—offering renewed hope for improved vision outcomes.
What are the most recent clinical trials for macular edema?
Several recent clinical trials are shedding light on potential advancements in the treatment of macular edema. In one Phase 2 trial, 4D-150 is being investigated for its efficacy in addressing this condition. Another Phase 2 study focuses on the foselutoclax arm and its impact on macular edema. Similarly, a Phase 2 trial is examining the effects of B1: OXU-001 at a mid dose level. Furthermore, another promising approach involves exploring different dosage levels in both Phase 1 and Phase 2 studies to determine their effectiveness against macular edema. Additionally, a separate Phase 4 trial investigates cataract surgery with Dextenza alongside a less frequent gtt regimen as an intervention for macular edema treatment optimization. These exciting endeavors hold promise for improving outcomes and providing relief to individuals suffering from macular edema.
What macular edema clinical trials were recently completed?
Recent clinical trials have made significant progress in the field of macular edema, a condition affecting the central part of the retina. Among these trials, Curacle Co., Ltd.'s study on multiple doses of CU06-1004 concluded successfully in July 2021. Unity Biotechnology, Inc.'s trial for UBX1325 reached completion in June 2021, while Ocuphire Pharma, Inc.'s investigation into APX3330 wrapped up in April 2021. In pursuit of effective treatments for macular edema, researchers from various organizations such as Hoffmann-La Roche and Novartis Pharmaceuticals have also conducted trials on Faricimab (completed March/December 2021), AXT107 (completed December 2020), MHU650 (completed December 2020), KSI-301 (completed September 2020), Aflibercept (completed May 2020), AR-13503 (completed June 2019), and LKA651 (completed May 2019). These collective efforts hold promise for improving outcomes for individuals affected by this vision-threatening condition.